05-1478
Anti-RUNX2 Antibody, clone AS110
clone AS110, from mouse
Synonym(s):
Acute myeloid leukemia 3 protein, CBF-alpha 1, Core-binding factor subunit alpha-1, Oncogene AML-3, Osteoblast-specific transcription factor 2, PEA2-alpha A, PEBP2-alpha A, Polyomavirus enhancer-binding protein 2 alpha A subunit, SL3-3 enhancer factor 1
Sign Into View Organizational & Contract Pricing
Select a Size
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
AS110, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG2b
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... RUNX2(860)
General description
54-57 kDa
RUNX2 (Runt-related transcription Factor) is a transcription factor that binds to its canonical consensus sequence 5’- PYGPYGGT-3’ in a number of promoters and enhancers. They include LCK, T-cell receptor enhancers, and various bone related genes such as osteocalcin, osteopontin, and bone sialoprotein. As a result of this, RUNX2 is involved in osteoblastic differentiation and skeletal morphogenesis. RUNX2 contains a proline/serine/ threonine-rich region at its C-terminus that has shown to be critical for its transcriptional activity.
Immunogen
Epitope: Internal
GST-coupled recombinant protein corresponding to amino acids 311-415 of human RUNX2.
Application
Anti-RUNX2 Antibody, clone AS110 detects level of RUNX2 & has been published & validated for use in WB & IC.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Biochem/physiol Actions
Detects RUNX2
Other species have not been tested.
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal in 0.1M Tris-Glycine (pH 7.4) with 150mM NaCl and 0.05% NaN3.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
Analysis Note
Routinely evaluated by Western Blot.
Western Blot Analysis:
Anti-RUNX2, clone AS110 detected RUNX at 1:1,000 to 1:2,000 dilution in HL-60 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Western Blot Analysis:
Anti-RUNX2, clone AS110 detected RUNX at 1:1,000 to 1:2,000 dilution in HL-60 cell lysate resolved via SDS-PAGE and transferred to PVDF.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Wei Yu et al.
Frontiers in endocrinology, 11, 583105-583105 (2020-11-27)
Inhibition of neuropeptide Y1 receptor stimulates osteogenesis in vitro and in vivo. However, the underlying mechanisms involved in these effects remain poorly understood. Here we identify the effects of Y1 receptor deficiency on osteogenic differentiation in human bone marrow stromal
Tzong-Shi Lu et al.
Cardiovascular research, 96(3), 524-532 (2012-08-31)
Vascular calcification (VC) is a significant contributor to cardiovascular mortality in patients with chronic kidney disease (CKD) and coronary artery disease (CAD). Osteo/chondrocytic transformation and simultaneous dedifferentiation of smooth muscle cells (SMCs) are important in the pathogenesis of VC. Heat-shock
Zhe Shi et al.
International journal of nanomedicine, 16, 5603-5619 (2021-08-26)
Given that autologous bone graft for bone defects is limited by insufficient supply and morbidity at the donor site, developing biomimetic graft materials as an alternative has gained consistent attention. However, obstacles in designing bone-mimetic materials that could integrate the
Zhe Shi et al.
International journal of nanomedicine, 15, 9337-9353 (2020-12-03)
Autologous bone grafts are the gold standard for treating bone defects. However, limited bone supply and morbidity at the donor site restrict its extensive use. Therefore, developing bone graft materials as an alternative to autologous grafts has gained considerable attention.
Kenneth Lim et al.
Circulation, 125(18), 2243-2255 (2012-04-12)
Klotho is known to function as a cofactor for the phosphatonin, fibroblast growth factor (FGF)-23 at the kidney. FGF-23 levels rise in chronic kidney disease (CKD) despite progression of accelerated vascular calcification. There are currently conflicting data on whether FGF-23
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 05-1478 | 04053252743986 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service